Kodiak Sciences Inc - Company Profile
Powered by 
All the data and insights you need on Kodiak Sciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Kodiak Sciences Inc Strategy Report
- Understand Kodiak Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kodiak Sciences Inc (Kodiak Sciences) is a clinical-stage biopharmaceutical company that develops therapies for the treatment of chronic and high-prevalence ophthalmic diseases. The company pipeline products includes KSI 301 an anti-VEGF biologic development, which offers wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy; KSI-501 an anti-IL6 and anti-VEGF bispecific biopolymer conjugate; and KSI-601 a triplet biopolymer conjugate, which treats dry age-related macular degeneration. Kodiak Sciences utilizes proprietary Antibody Biopolymer Conjugate (“ABC”) Platform, that combines biologics design with next generation phosphorylcholine biopolymers. It commercializes technology to both bio-pharmaceuticals and small molecules companies. The company operates in the US and Switzerland. Kodiak Sciences is headquartered in Palo Alto, California, the US.
Headquarters
United States of America
Address
1200 Page Mill Rd, Palo Alto, California, 94304
Website
kodiak.com
Telephone
1 650 2810850
No of Employees
116
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KOD (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-25%
(2022 vs 2021)
Market Cap*
$161.1M
* As of and is in US$
Kodiak Sciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline Product: |
| KSI 301: |
| Retinal Vein Occlusion |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Others | In August, the company completed enrollment in its GLOW Phase 3 clinical trial of tarcocimab tedromer, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with Non-Proliferative Diabetic Retinopathy without diabetic macular edema. |
| 2022 | Corporate Changes/Expansions | In May, the company and Lonza Group opened a new bioconjugation facility in Visp, Switzerland. |
| 2022 | Official Trials/Tests | In February, the company announced results from its initial Phase 2b/3 study of KSI-301 in patients with neovascular (Wet) age-related macular degeneration. |
Competitor Comparison
| Key Parameters | Kodiak Sciences Inc | Flexion Therapeutics Inc | Ocular Therapeutix Inc | Axsome Therapeutics Inc | Apoplogic Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Palo Alto | Burlington | Bedford | New York | Aurora |
| State/Province | California | Massachusetts | Massachusetts | New York | Colorado |
| No. of Employees | 116 | 257 | 274 | 383 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Victor Perlroth, MD | Chief Executive Officer; Chairman | Executive Board | 2009 | 49 |
| John Borgeson | Senior Vice President; Chief Financial Officer | Senior Management | 2016 | 60 |
| Michael S. Louie | Chief Information Officer; Senior Vice President - Digital Transformation | Senior Management | - | - |
| Hong Liang, Ph.D. | Senior Vice President - Discovery Medicine | Senior Management | 2015 | 48 |
| Almas Qudrat, M.Sc. | Senior Vice President - Quality Operations | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward